PubMed · 2018 · 59 citations · 35 references
MedicinePharmacologyPharmacotherapyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer PharmacotherapyCancer ChemopreventionCytotoxic ChemotherapyHormonal TherapyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityAnticancer Compound ScreeningAntiproliferative AgentsAntiproliferative Drug ActionBreast Cancer ChemopreventionCytotoxicity AssaysMetformin InteractionsReal-time Polymerase Chain Reaction (Pcr)
OBJECTIVES: Breast cancer remains a global challenge, and further chemopreventive therapies are still immediately required. Emerging evidence has revealed the potent anti-cancer effects of biguanides, Metformin (MET) and phenformin (PHE). Thus, to explore an efficient chemopreventive strategy for breast cancer, the antiproliferative effects of the combination of MET and PHE against breast cancer cells were assessed. MATERIALS AND METHODS: Cytotoxicity of the drugs individually and in combination against T47D and MDA-MB-231 breast cancer cells were assessed using MTT assay and the median-effect method was used to analyze the precise nature of the interaction between MET and PHE. Besides, the expression levels of hTERT after 48 hr drug exposure were determined using qRT-PCR. RESULTS: <0.001). CONCLUSION: It is speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.
35
Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells
Mahvash Zakikhani, Ryan J.O. Dowling, I. George Fantus et al. · Cancer Research · 2006 · 1K citations · Full text
Irina Alimova, Bolin Liu, Zeying Fan et al. · Cell Cycle · 2009 · 525 citations · Full text
Medicine, Oncology, Pharmacology +17